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Phytanic acid (3,7,11,15-tetramethylhexadecanoic acid) is a branched chain fatty acid, which is a constituent of the human diet. The presence
of the 3-methyl group of phytanic acid prevents degradation by beta-oxidation. Instead, the terminal carboxyl group is first removed by alpha-
oxidation. The mechanism of the alpha-oxidation pathway and the enzymes involved are described in this review.
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Although phytanic acid had been isolated from cow milk
already in the 1950s [1] and its structure has been known since
the 1960s [2,3], at that time this multi-branched fatty acid did
not get any special attention. The discovery of high amounts of
phytanic acid in kidney, liver, and brain of patients suffering
from Refsum's Syndrome, however, initiated a long period of
research on its metabolism. As phytanic acid (3,7,11,15-
tetramethylhexadecanoic acid) has a methyl-residue at the
third carbon atom of its backbone, it was immediately
recognized that degradation could not occur by beta-oxidation.
An alternative catabolic pathway was proposed, involving
removal of the alpha carbon unit as CO2. Accordingly, this
process was named alpha-oxidation. After several decades of
research, the enzymatic steps involved in this pathway have
been resolved now, and two different enzymatic and genetic
causes of Refsum Disease have been elucidated. However, even
today not all enzymes involved in the alpha-oxidation pathway
have been isolated and characterized, nor have all correspond-
ing genes been found. This review provides a description of the
current knowledge about the alpha-oxidation process.⁎ Corresponding author.
E-mail address: g.a.jansen@amc.uva.nl (G.A. Jansen).
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In studies on the fatty acid composition of bovine milk fat
carried out in the early 1950s, a multi-branched C20 fatty acid
was isolated [1]. It took 10 years, however, before the structure
of this fatty acid could be characterized using analytical
techniques including gas chromatography-mass spectrometry
and nuclear magnetic resonance [2,3]. These analyses revealed
that this fatty acid, which was named phytanic acid, contains 4
methyl residues on a C16 backbone. Accordingly, phytanic acid
could be assigned the systematic name 3,7,11,15-tetramethyl-
hexadecanoic acid.
2.1. The origin of phytanic acid
Phytanic acid has been found in man (it has been detected in
plasma, liver and other organ tissues, milk and sciatic nerve),
but also in other mammals, as well as in birds, fish, micro-
organisms and their lifeless remains. For instance, phytanic acid
was demonstrated to be present in cows (in rumen contents,
depot fats, liver), rats (serum), rabbits (serum), pigs (depot fats),
deer (depot fats), whales (blubber oil and milk), ovine faeces,
fish oil, earthworms, Antarctic and Atlantic krill, crude
petroleum, ancient and recent sediments at levels varying
around 0.01–0.3% of the total fatty acids. Relatively high
amounts of phytanic acid were found in Antarctic krill and
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respectively) and earthworms, which contain 1.9% in winter
until as much as 3.5% in summer. Very high levels of phytanic
acid (8% of total fatty acids) were found in cows fed for several
months with ensilage (for reviews see [4,5]).
2.2. Phytanic acid in man
The presence of phytanic acid in man was first reported in
1963 by Klenk and Kahlke [6] who found phytanic acid in
lipid fractions of liver, kidney, and brain of a patient
suspected to suffer from Refsum's Syndrome. This neurolo-
gical syndrome was first described in 1946 by the Norwegian
physician Sigvald Refsum [7] and initially called heredopathia
atactica polyneuritiformis. Presently, this syndrome is com-
monly known as Refsum Disease (RD), but is sometimes also
referred to as Refsum's Disease or Adult Refsum Disease
(ARD).
In later studies it was discovered that phytanic acid
accumulation is not a unique feature for Refsum Disease, but
also occurs, to a lesser extent, in patients suffering from the
group of peroxisome biogenesis disorders (PBDs), including
Zellweger Syndrome (ZS), Neonatal Adrenoleukodystrophy
(NALD), Infantile Refsum Disease (IRD) and Rhizomelic
Chondrodysplasia Punctata type 1 (RCDP1). This observation
suggested involvement of peroxisomes in the metabolism of
phytanic acid.
2.2.1. Endogenous synthesis
Phytol has a poly-isoprenoid structure and differs from
phytanic acid in having a Δ2 double bond and an alcohol-group
rather than a carboxylic acid-group at the first carbon atom.
Isoprene units, the building blocks for poly-isoprenoids, are
synthesized form three acetate molecules to form mevalonate,
which is converted to the isoprene unit isopentenylpyropho-
sphate. In plant chloroplasts, phytol is synthesized by coupling
four isoprene units, followed by reduction of the Δ6, Δ10, and
Δ14 double bonds in the backbone of the molecule [8]. As
phytanic acid also has a poly-isoprenoid structure it was
postulated that phytanic acid could be synthesized in a similar
pathway. One of the final steps in this hypothetical pathway
would involve the addition of an isoprene unit to farnesol,
producing geranylgeraniol. In order to obtain phytanic acid, the
double bonds in geranylgeraniol would have to be reduced, and
the alcohol-group converted to a carboxylic acid. All precursors
for this hypothetical biosynthetic route are available in the
human body: farnesol, which plays a role in the farnesylation of
proteins, is present in many cell types, and isoprene units, the
building blocks for steroids, are also abundant. However, when
[2-14C1]mevalonic acid was administered to a patient with
Refsum Disease, no incorporation of the label into phytanic acid
was found [9–11]. Similar experiments in animals using
labelled mevalonic acid and labelled acetate revealed that
these potential precursors were not incorporated into phytanic
acid [9]. These data have led to the conclusion that phytanic
acid is not derived from endogenous synthesis in humans and
animals.2.2.2. Dietary phytol and its conversion to phytanic acid
Phytol (3,7,11,15-tetramethylhexadec-trans-2-ene-1-ol) dif-
fers in structure from phytanic acid in having a double bond at
the first carbon atom and containing an alcohol function instead
of a carboxyl-group. Phytol is the alcohol moiety of the
chlorophyll molecule and, as an integral part of chlorophyll, it is
abundantly present in plants and even more ubiquitous in the
marine environment, mainly in planktonic algae [12]. Bound to
the chlorophyll molecule, however, humans and rats are not able
to absorb this compound effectively [13], which implies that it
cannot be a significant dietary precursor of phytanic acid.
Phytol can be released from chlorophyll by the action of
bacteria present in the rumen of ruminant animals. The resulting
free phytol can either be converted to phytanic acid in the rumen
of animals or effectively absorbed by both humans and animals
[9,13,14].
The conversion of phytol to phytanic acid may proceed via
two distinct routes. The first route starts with hydrogenation of
phytol yielding dihydrophytol, followed by an oxidation step to
form phytanic acid. This route is demonstrated to take place in
the rumen of ruminant animals [15–17], and is carried out by
resident micro-organisms. The resulting phytanic acid is
absorbed by the animal.
The second breakdown pathway was postulated based on the
observation that, when free phytol was fed to rats (being a non
ruminant), phytanic acid was produced [10], but hardly any
dihydrophytol could be detected in plasma and tissues [14].
Further animal studies in various mammals including mouse,
rat, rabbit, and chinchilla, showed that upon feeding of phytol
not only phytanic acid levels, but also phytenic acid levels
increased [10,14]. This has led to the hypothesis that in
mammals, phytol is first converted to phytenal, a process which
is known to exist in marine bacteria [18], most likely by the
action of an alcohol dehydrogenase. Phytenal may then be
converted by an aldehyde dehydrogenase to form phytenic acid.
Subcellular localization studies in rat have shown that the
production of phytenic acid from phytol mainly occurs in
mitochondria- and microsome-enriched fractions [19,20].
Based on the observation that in man, the microsomal fatty
aldehyde dehydrogenase (ALDH3A2, encoded by the
ALDH3A2 gene) is accepting dihydrophytal as a substrate,
van den Brink and co-workers have studied the involvement of
this enzyme in the metabolism of phytol. To this end, the
ability of both ALDH3A2 deficient cultured fibroblasts
(obtained from patients suffering from Sjögren Larssen
syndrome (SLS), which is characterized by ALDH3A2
deficiency), and control cell lines was investigated. It was
shown that phytenic acid was produced from phytol in
fibroblasts from controls, but not in fibroblasts from patients
with SLS [21], indicating the involvement of ALDH3A2 in
human phytol metabolism.
Muralidharan and Muralidharan [19] have suggested that in
mammals, analogous to marine bacteria [18], phytenic acid may
be reduced to form phytanic acid, supposedly catalyzed by an
NADPH dependent reductase, although the enzyme involved
had not been characterized. Recent studies presented evidence
that this might not be the only possible conversion. First, it was
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phytenoyl-CoA, was converted much more efficiently than
free phytenic acid [22], and that phytanoyl-CoA was produced
in an NADPH dependent manner. If this breakdown route were
true, phytenic acid would need to be activated to phytenoyl-
CoA. Based on the finding that free phytanic acid can be
activated by long chain acyl-CoA synthetase [23], it was
demonstrated that phytenic acid is indeed activated at almost the
same reaction rate as phytanic acid, by incubation of the free
fatty acids with rat liver homogenate, followed by measurement
of phytenoyl-CoA and phytanoyl-CoA formation, respectively
[22]. Moreover, it was shown that phytenoyl-CoA is produced
in cultured rat hepatocytes grown on a phytol containing
medium, demonstrating that phytenoyl-CoA is a true inter-
mediate in the breakdown of phytol.
Recent work by Gloerich and colleagues has led to the
identification of the enzyme catalyzing the conversion of
phytenoyl-CoA to phytanoyl-CoA [24]. The enzyme involved,
human peroxisomal trans-2-enoyl-CoA reductase (PECR), had
been identified earlier by Das and co-workers, who proposed it
would play a role in fatty acid chain elongation [25], but
Gloerich et al. now showed that PECR catalyzes the conversion
of phytenoyl-CoA to phytanoyl-CoA in an orthologous
expression system in E. coli [24].
Taken together, it is likely that the end product of the phytol
degradation pathway is not phytanic acid, but rather its activated
form, phytanoyl-CoA. This hypothesis is logical in the sense
that phytanoyl-CoA is the direct substrate for alpha-oxidation,
as will be discussed below.
As can be concluded from the studies described above,
phytol bound to chlorophyll as present in plants and vegetables
plays no important role as precursor of phytanic acid in non
ruminants as chlorophyll is poorly absorbed. Although cooking
of vegetables may release some phytol which can be absorbed
by humans, this is of little significance when compared to the
total amount of dietary phytanic acid (see below), as it
comprises less then 10% of the dietary phytanic acid intake.
However in ruminants, which display much higher phytanic
acid levels in plasma as compared to humans (5–10% and
<0.1% of total fatty acids, respectively [26]) the chlorophyll
derived phytol is the major source of phytanic acid. The
contribution of free phytol to the total phytanic acid load in the
human diet is unclear yet, and should be resolved by phytol
measurements in food stuffs. To accomplish this, however, a
reliable and preferably inexpensive method to measure phytol in
components of the human diet has to be developed, as such a
method is currently not available.
2.2.3. Dietary phytanic acid
The average daily intake of phytanic acid in humans is about
50–100 mg, but this amount is strongly dependent on the
composition of the diet. Relatively high amounts of phytanic
acid are found in dairy products (butter, cheese) and ruminant
fats as present in meat products. These levels may vary
considerably, dependent on the ruminants' diet: phytanic acid
levels may raise from 0.01% of the total fatty acids when
feeding on pasture, up to 8% when the cows are fed silage for 6months, indicating that there is a huge fluctuation during the
seasons. Next to the ruminant products, also fish (tuna, cod),
fish oil, and vegetable oils are rich in phytanic acid [5,27,28].
Phytanic acid is well absorbed by humans and other mammals
(rats, mice), and is rapidly degraded. The elucidation of the
metabolic route to degrade phytanic acid will be discussed in
detail below.
3. Phytanic acid alpha-oxidation
In studies on phytanic acid alpha-oxidation starting in the
1960s until the mid 1990s, many controversial results have been
produced, adding to the confusion about the mechanism and the
subcellular localization of the alpha-oxidation pathway.
In vivo experiments in both humans and animals (mostly
rats), and studies in intact cell systems including cultured skin
fibroblasts, showed that when labelled (either uniformly
[U-14C20], or specifically at the first carbon atom [1-
14C1], or
[1-13C1])phytanic acid was administered, production of labelled
2-hydroxyphytanic acid, CO2 and pristanic acid was detected
[10,11,29]. In patients with Refsum Disease, production of
2Qhydroxyphytanic acid was deficient [29,30], whereas break-
down of 2-hydroxyphytanic acid and pristanic acid was found
to proceed normally [30]. These data have led to the hypothesis
that phytanic is first converted to 2-hydroxyphytanic acid and
subsequently to pristanic acid [31], and that the first conversion
step is deficient in Refsum Disease.
An indication that peroxisomes are at least in part involved in
alpha-oxidation was provided by the finding that phytanic acid
accumulates in patients suffering from a peroxisome biogenesis
disorder, which includes Zellweger Syndrome, Neonatal
Adrenoleukodystrophy, and Infantile Refsum Disease. How-
ever, cell fractionation studies using human and animal tissues,
have resulted in conflicting reports. Most studies elaborated on
the concept of the free fatty acid being the substrate for alpha-
oxidation, and used CO2 production as measure of alpha-
oxidation activity. In liver from rat and guinea pig, mitochondria
were reported to be the main site for alpha-oxidation [32–34],
although later the requirement of a cytosolic factor was
suggested [35]. Mitochondria were also the apparent alpha-
oxidation site in human [36–38] and monkey liver [36]. Using
different assay conditions, even the endoplasmic reticulum has
been suggested as site for phytanic acid oxidation, at least in rat
liver [39]. The first study which reported a peroxisomal
involvement was performed in cultured skin fibroblasts [40].
Oxidation was found to be dependent on the presence of ATP,
Mg2+ and CoA, suggesting that phytanic acid needs to be
activated to its CoA-ester prior to oxidation. Remarkably, under
the same conditions, a mitochondrial location was found for rat
fibroblasts and liver [41]. In search for the activating enzyme,
i.e. phytanoyl-CoA ligase, additional studies by the same
authors further suggested species dependent localization of this
ligase, which they found to be peroxisomal in human liver and
fibroblasts, but microsomal and to a lesser extent mitochondrial
in the rat [42].
Retrospectively, many of these conflicting findings can now
be explained, as in most studies the absolutely essential
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following two key findings have led to the resolution of the
alpha-oxidation pathway in the last decades:
(1) Formic acid and not CO2 is the primary reaction product
of phytanic acid oxidation [43]. The amount of formic
acid was shown to be about 9-fold higher as compared to
CO2, which is subsequently formed from formic acid as a
secondary product. This finding implied that in all studies
in which CO2 production was used as a measure for
enzyme activity, the rates of phytanic acid oxidation have
been grossly underestimated. Furthermore, subcellular
localization studies became even less reliable, as it is not
known whether CO2 production from formic acid occurs
in the same organelle as phytanic acid alpha-oxidation.
(2) Phytanic acid has to be activated to phytanoyl-CoA prior
to alpha-oxidation [44]. The authors used [2,3-3H]
phytanoyl-CoA as substrate for rat liver peroxisomes
and showed that 3H was released. This conversion could
only be the result of the 2-hydroxylation of the CoA-ester.
In addition, formate was produced in these incubations.
Further studies revealed that the hydroxylating enzyme is
dependent on the presence of Fe2+, ascorbate, and 2-
oxoglutarate [45]. Especially the absolute dependence on
2-oxoglutarate implicated that all previous studies should
be considered with great caution, as in none of them this
compound had been added to the incubation medium.
After years of debate, consensus has now been reached about
the concept of activation of phytanic acid prior to alpha-
oxidation, and below the individual steps of this pathway will
be described. The subcellular localization of the phytanic acid
alpha-oxidation pathway has been established and is predomi-
nantly, if not exclusively, peroxisomal.
3.1. Activation and import into peroxisomes of phytanic acid
Despite the fact that Watkins and co-workers provided the
first conclusive evidence for the requirement of activation of
phytanic acid already in 1994 [44], there is no consensus in
literature on the site of phytanic acid activation and the enzymes
involved. According to Pahan and Singh, phytanic acid is
activated by a distinct acyl-CoA synthetase which they
suggested to be localized in peroxisomes in human liver and
fibroblasts, but localized in mitochondria and microsomes in rat
liver and fibroblasts [42]. Studies by Watkins and co-workers
have provided evidence against the existence of a distinct
phytanoyl-CoA synthetase [23]. These authors expressed the
cDNA encoding the long-chain acyl-CoA synthetase (ACSL1)
in an in vitro transcription/translation system, and established
that ACSL1 has also affinity for phytanic acid. Interestingly,
this enzyme was first thought to be present in peroxisomes,
mitochondria and microsomes, but more recent studies by
Lewin and co-workers have shown that this is not true: ACSL1
(alias ACS1) is present in peroxisomes and mitochondria-
associated membranes (MAM), but not in mitochondria, at least
not in rat liver [46]. The catalytic site of this enzyme is exposedto the cytosol which implies that the formation of phytanoyl-
CoA occurs in the extra-peroxisomal space, thus requiring a
mechanism to shuttle phytanoyl-CoA across the peroxisomal
membrane. In literature no data are available on a putative
translocator catalyzing the trans-membrane transport of phyta-
noyl-CoA into peroxisomes.
As an alternative mechanism, phytanic acid could be
translocated over the peroxisomal membrane as free fatty
acid, followed by activation inside the peroxisome. Human
very-long-chain acyl-CoA synthetase (VLACS, encoded by the
SLC27A2 gene) is present in the peroxisomal membrane, has
been shown to face the peroxisomal matrix, and is capable of
activating phytanic acid [47], demonstrating the feasibility of
this route. In order to study this possible role of VLCS in
phytanic acid metabolism, the Slc27a2 knock-out mouse [48]
would be a useful tool.
3.2. 2-Hydroxylation by phytanoyl-CoA hydroxylase
(PhyH/Pahx)
The first step of the alpha-oxidation pathway involves the
2Qhydroxylation of phytanoyl-CoA to form 2-hydroxyphyta-
noyl-CoA. Studies in rat liver peroxisomes using [1-14C1]
phytanic acid by Mihalik et al, showed that indeed [1-14C1]2-
hydroxyphytanoyl-CoA was produced, and that this reaction
was dependent on Fe2+, ascorbate, and 2-oxoglutarate [45]. The
latter compounds are known to be cofactors and co-substrate for
the enzyme class of oxygenases. In addition, the incubations
yielded labelled formic acid and CO2, suggesting that in a
subsequent step formic acid is produced, which eventually is
converted to CO2, in line with previous studies by Poulos and co-
workers [43]. These important findings were confirmed by
ourselves [49] and Croes and co-workers [50]. The latter authors
showed that in rat liver the model substrates 3-methylheptade-
canoic acid and 3-methylhexadecanoic acid also undergo
2Qhydroxylation, dependent on Fe2+, ascorbate, and 2-oxoglu-
tarate, and that formic acid and CO2 are produced [50,51].
The assay system used by Mihalik and co-workers in the
studies mentioned above had been optimized for use in purified
subcellular (peroxisomal) fractions, where [1-14C1]phytanic
acid rather than the true substrate phytanoyl-CoA, was used as
pro-substrate, and ATP, Mg2+, CoASH together with purified
microsomes were included as a source for synthetase to generate
phytanoyl-CoA. However, when this assay-system was applied
to activity measurement in total liver homogenates, a rapid
hydrolysis of phytanoyl-CoA was observed after addition of
liver homogenate to the reaction mixture, indicating that hepatic
hydrolases are more abundant in total homogenates when
compared to purified peroxisomes and microsomes [52]. This
problem was overcome by using phytanoyl-CoA as a substrate,
and incubation in the presence of ATP, Mg2+, and CoASH,
which proved sufficient to maintain constant levels of
phytanoyl-CoA for at least 30 min [49,52]. Subsequent activity
measurements in human liver showed that phytanoyl-CoA
hydroxylase (PhyH) has high activity in human liver, is
localized in peroxisomes, and is deficient in liver biopsies
from patients suffering from Zellweger syndrome [49]. A
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from patients with RCDP type 1 [53]. As patients with RCDP
type 1 lack Pex7p, and are therefore incapable of importing
proteins equipped with a PTS2 target sequence into peroxi-
somes, this finding strongly suggested that PhyH is a
peroxisomal protein and contains a PTS2.
Another important finding was the discovery that PhyH
activity is also deficient in a liver specimen from a patient with
Refsum Disease, which resolved the molecular mechanism of
this disorder [54]. Following up on this finding, PHYH (in
literature also referred to by its alias PAHX), the gene encoding
phytanoyl-CoA hydroxylase was cloned [55,56], and it was
demonstrated that a large set of patients suffering from Refsum
Disease carry sequence variants in PHYH [55–58].
Structure based studies on the enzymatic properties of PhyH
and its reaction mechanism have been performed initially by
Mukherji and co-workers [59]. Sequence comparisons and
crystallographic data of the enzyme family of 2-oxoglutarate
dependent oxygenases led these authors to predict secon-
dary structure elements of PhyH, including the Fe2+ and 2-
oxoglutarate binding domains. The Fe2+ binding domain
comprises the three amino acid sequence HXD, in PhyH at
positions 175–177. Site directed mutagenesis of this motif,
using p.H175A and p.D177A, abolished hydroxylation of
phytanoyl-CoA in vitro [59], and also sequence variants of this
domain observed in patients with Refsum Disease, p.Q176K
and p.D177G, caused strong reduction of PhyH activity [57].
Also, the p.Q176K variant uncouples the hydroxylation of
phytanoyl-CoA from the 2-oxoglutarate utilization, as the 2-
oxoglutarate to succinate conversion is reduced to 57% of the
control rate, whereas residual hydroxylation activity is only
16% [59]. Furthermore, binding of 2-oxoglutarate was impaired
when p.R275 was substituted, strongly suggesting its involve-
ment in the 2Qoxoglutarate binding domain. Interestingly, the p.
R275Q substitution, which is also observed in two patients with
Refsum Disease, results in a complete loss of catalytic activity
when 2Qoxoglutarate is used as co-substrate, but when 2-
oxobutyrate is used in in vitro experiments as alternative co-
substrate, PhyH activity is partially restored. Two other
substitutions, p.R275A and p.R275W, do not display restoration
of enzymatic activity. This 'substrate rescue' may have potential
for treatment of patients with Refsum Disease with this specific
sequence variation. However, first this concept needs to be
further evaluated, starting with in vivo studies.
Another peculiar finding was the observation that two
sequence variants, p.G204S and p.N269H, cause the uncou-
pling of the hydroxylation of phytanoyl-CoA and the conver-
sion of the co-substrate 2-oxoglutarate into succinate and
CO2. In these two variants no hydroxylation occurs, but
2Qoxoglutarate is still converted at 40% of its normal reaction
rate, basically the same phenomenon as observed with the p.
Q176K variant, which is located in the Fe2+ binding domain, as
described above.
Crystallization studies by McDonough and co-workers have
recently revealed the molecular structure of PhyH [60]. This
structural knowledge has enabled a better understanding of the
enzymatic mechanism of PhyH, and confirmed all hypothesesregarding the Fe2+ and 2-oxoglutarate binding domains
described above. Moreover, this structural information also
allows more detailed predictions on the consequences of
sequence variations in Refsum Disease, and possible interven-
tions therein.
3.3. Conversion of 2-hydroxyphytanoyl-CoA to pristanal by
2-hydroxyphytanoyl-CoA lyase
The second step of the alpha-oxidation pathway involves the
decarboxylation of 2-hydroxy-phytanoyl-CoA. Initially it has
been hypothesized that pristanoyl-CoAwould be the product of
phytanic acid alpha-oxidation, but surprisingly, pristanic acid
was found to be the end product [61]. This finding has led to the
postulate that 2-hydroxyphytanoyl-CoA first is converted to the
fatty aldehyde pristanal and formyl-CoA by the action of a
lyase. Indeed, incubation of human liver homogenate in the
presence of 2-hydroxyphytanoyl-CoA yielded pristanal as
product [62]. Addition of NAD as cofactor for a putative
aldehyde dehydrogenase possibly catalyzing the subsequent
dehydrogenation of pristanal, resulted in the production of
pristanic acid, which indicated that this proposed pathway
might be correct. The enzyme catalyzing the decarboxylation of
2-hydroxyphytanoyl-CoA was named 2-hydroxyphytanoyl-
CoA lyase (2-HPCL). This enzyme has been purified by
Foulon and co-workers and was found to be localized in
peroxisomes in rat liver, and dependent on thiamine pyropho-
sphate (TPP) and Mg2+ [63]. Cloning of the encoding gene
(HACL1) revealed the presence of an hitherto unrecognized
PTS1 signal (-SNM, preceded by a positive charge: in this case
RSNM), which directs 2-HPCL to peroxisomes, as transfection
experiments with GFP-2-HPCL fusion protein have shown a
peroxisomal localization in Pex5+/−, and a cytosolic localization
in Pex5−/− mouse cell lines.
Although it had previously been demonstrated that formate
was produced in this step [43], now it was also demonstrated
that in fact formyl-CoA is the primary product of this
decarboxylation [63,64]. Formyl-CoA, which was shown to
be instable at neutral pH, spontaneously splits into formate and
CO2 [64], explaining the previous observations of formate
production in this step. The fate of formate within peroxisomes
is unclear. A good candidate for the subsequent oxidation of
formate would be catalase. This enzyme detoxifies hydrogen
peroxide by catalyzing the conversion of 2H2O2 to 2H2O+O2,
but also may act as a more general peroxidase catalyzing the
reaction H2O2+RH2 to 2H2O+R, in which hydrogen peroxide
is used to oxidize various compounds (R) such as phenols,
alcohols, formaldehyde, and also formic acid. The capability of
catalase to oxidize formic acid has already been reported in
1948 by Chance [65].
3.4. Dehydrogenation of pristanal by an aldehyde
dehydrogenase
The last step in phytanic acid alpha-oxidation involves the
conversion of pristanal to pristanic acid. This reaction is carried
out by an NAD(P) dependent fatty aldehyde dehydrogenase, as
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[62,66]. Based on a single experiment in human liver only, it
was suggested that this conversion may take place in the
endoplasmic reticulum [61]. The possible involvement of the
fatty aldehyde dehydrogenase ALDH3A2 was investigated
using cell lines from patients with Sjögren Larssen syndrome
(SLS), characterized by a microsomal ALDH3A2 deficiency. It
was shown that [2,3-3H]phytanic acid oxidation occurred at less
than 25% of the control rate [66], indicating a role of
ALDH3A2 in alpha-oxidation. This hypothesis is not very
appealing, as it would imply the transport of pristanal from
peroxisome to endoplasmic reticulum, followed by transport of
pristanic acid in the opposite direction for further beta-oxidationFig. 1. The phytanic acid alpha-oxidation pathway. The top of this scheme shows the d
to phytanoyl-CoA and subsequently undergo alpha-oxidation. See text for details.in peroxisomes. A more attractive idea would be the existence
of an aldehyde dehydrogenase within peroxisomes. This
aldehyde dehydrogenase activity in peroxisomes was demon-
strated in rat liver [64,67]. Moreover, studies in fibroblast
homogenates from patients with SLS showed more than 25%
residual activity for pristanal conversion, whereas dehydro-
genation of other aldehydes such as octanal was almost
completely deficient [67]. These observations indicated that
microsomal ALDH3A2 may not be the main catalyst in
pristanal degradation.
The existence of many (at least more than ten) different
aldehyde dehydrogenases [68], some with a poorly charac-
terized subcellular localization, have complicated detailedietary input of phytanic acid. Phytol, also a dietary component, can be converted
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substrate specificities, and several may be capable of pristanal
conversion. Several attempts to purify a peroxisomal pristanal
converting aldehyde dehydrogenases have led to the isolation of
(microsomal) ALDH3A2 (van den Brink, personal commu-
nication). Despite being qualified as a microsomal enzyme,
ALDH3A2 is still a possible candidate for pristanal conversion
for the following reasons: first, a bimodal localization between
peroxisomes and ER has been reported [69,70], although this
has been rejected by others [71,72]. Second, different splice
variants of ALDH3A2 (encoded by the ALDH3A2 gene) occur,
one of which lacks the targeting sequence for the endoplasmic
reticulum, which may well lead to a different subcellular
localization. Third, a hypothesis for the biogenesis of peroxi-Fig. 2. Schematic representation of the degradation of phytanic acid and pristanic acid
the bottom half of this scheme, may follow route 1 or 2 before transport across thesomes involves the budding of ER membranes to form
peroxisomal membranes, thus allowing the incorporation of
originally ER proteins in peroxisomes. Conclusive evidence for
any of the mentioned ideas needs to be provided by future
studies.
An overview of the alpha-oxidation pathway is depicted in
Fig. 1.
3.5. Stereochemistry of the phytanic acid alpha-oxidation
pathway
In contrast to the peroxisomal beta-oxidation system, the
phytanic acid alpha-oxidation pathway is not stereo-selective
[73]. Indeed, the two naturally occurring stereo-isomersin peroxisomes. The products of the peroxisomal beta-oxidation, as depicted in
peroxisomal membrane and transfer to the mitochondria. See text for details.
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to their corresponding coenzyme A esters and alpha-oxidized
to produce (2R,6R,10R)- and (2S,6R,10R)-pristanic acid (see
Fig. 2).
3.6. Further catabolism of pristanic acid by the peroxisomal
beta-oxidation system
Early studies by Poulos and co-workers had already shown
that pristanic acid is not oxidized in mitochondria, but in
peroxisomes [74]. The first direct indication that pristanic acid
is indeed a substrate preferred by peroxisomes came from the
observation that pristanic acid levels in plasma are elevated in
patients lacking peroxisomes (such as Zellweger Syndrome).
Subsequent studies using radio-labelled pristanic acid have
confirmed this finding.
The site of activation of pristanic acid has not been
established with certainty but may well be different depending
on the source of pristanic acid. Indeed, early studies by one of us
have shown that pristanic acid can be activated at different
subcellular locations including peroxisomes, mitochondria and
endoplasmic reticulum. The activity localized in peroxisomes is
membrane-bound, with the site of catalytic activity exposed to
the cytosol [75]. This synthetase may well be involved in the
activation of pristanic acid derived from extra-peroxisomal
sources. However, as described above, a substantial part of
pristanic acid is generated inside peroxisomes by alpha-
oxidation of phytanic acid. It may well be that pristanic acid
generated inside peroxisomes is activated by the enzyme very
long-chain acyl-CoA synthetase (VLACS, encoded by the
SLC27A2 gene), which has a bimodal distribution in peroxi-
somes and endoplasmic reticulum, respectively [47]. Available
evidence suggests that this enzyme is peripheral membrane-
bound, with its catalytic site exposed to the peroxisomal lumen.
VLACS may be targeted to peroxisomes by a potential PTS1
signal, -LKL.
In contrast to the alpha-oxidation system, the peroxisomal
(and also mitochondrial) beta-oxidation system is stereo
selective and only accepts (2S)-acyl-CoA esters. This implies
that (2S)-pristanoyl-CoA can be directly degraded by the
peroxisomal beta-oxidation system, in contrast to (2R)-prista-
noyl-CoA, which first needs to be converted to (2S)-pristanoyl-
CoA. Peroxisomes contain alpha-methylacyl-CoA racemase
(AMACR, encoded by the AMACR gene) activity which allows
this conversion. Interestingly, AMACR is equipped with two
targeting signals, one at the carboxy-terminus and the other at the
amino terminus of the protein. The amino-terminal part contains
a mitochondrial targeting signal (MTS) whereas the carboxy-
terminus contains a peroxisomal targeting signal (PTS1).
Studies by Verhoeven and co-workers [76] have shown that
pristanoyl-CoA undergoes three cycles of beta-oxidation in
peroxisomes, yielding two molecules of propionyl-CoA, one
acetyl-CoA, and one 4,8-dimethylnonanoyl-CoA as end
products, which may be transported to the mitochondria for
further oxidation via one of the following routes. Route 1
involves the conversion of the acyl-CoAs in peroxisomes to
the corresponding carnitine-esters as mediated by the twoperoxisomal acyltransferases, i.e. carnitine acyltransferase
(CAT, encoded by the CRAT gene), which converts acetyl-
CoA and propionyl-CoA into their carnitine-esters, and
carnitine O-octanoyltransferase (COT, encoded by the CROT
gene), which converts 4,8-dimethylnonanoyl-CoA into
4,8Qdimethylnonanoylcarnitine. Route 2 involves hydrolytic
cleavage of the acyl-CoAs to form free fatty acids plus
coenzyme A, followed by the transfer of the fatty acids out of
the peroxisomes and into mitochondria for further oxidation
(see Fig. 2).
4. Concluding remarks
4.1. Additional substrates for alpha-oxidation: straight chain
fatty acids
Recent studies suggest that peroxisomes are involved in the
breakdown of 2-hydroxylated straight chain fatty acids. 2-
Hydroxy straight chain fatty acids are present in various tissues,
but most abundant in brain, as constituents of cerebrosides and
sulfatides, mostly found in myelin. It is unclear whether PhyH
can catalyze the hydroxylation of straight chain fatty acids, as
suggested by some [77], or not, as shown by others [73,78].
Alternatively, hydroxylation of straight chain fatty acids may
also be carried out by a distinct hydroxylase FA2H in brain [79].
It has been suggested that these 2-hydroxy fatty acid
compounds are broken down by alpha-oxidation. Foulon and
co-workers now have demonstrated that 2-hydroxy straight
chain fatty acids can indeed be alpha-oxidized in both intact and
broken cell systems from rat brain and liver, thereby producing
a fatty aldehyde, formyl-CoA and CO2 [80]. Furthermore, the
reaction was shown to be dependent on ATP, Mg2+, CoASH,
TPP, and NAD, exactly the same cofactors as needed for
peroxisomal phytanic acid alpha-oxidation as catalyzed by 2-
HPCL and the subsequent aldehyde dehydrogenase. Thus far,
only a few substrates with a limited number of chain lengths
have been studied. Additional studies will be needed to show
the range of substrates and their chain lengths that are degraded
by this pathway, but regardless of the results, these data already
strongly suggest an hitherto unrecognized role of peroxisomal
alpha-oxidation in brain lipid metabolism.
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